Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report

BACKGROUND: Asbestosis is characterized by lung and pleural fibrosis and by immune system dysregulation, with autoantibody production and systemic immune-mediated disease. No specific therapies are available for asbestosis. Recently, the pivotal pathogenic role exerted by interleukin-1beta has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Niccoli, Laura, Cassarà, Emanuele, Kaloudi, Olga, Nannini, Carlotta, Romagnoli, Micaela, Cantini, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465479/
https://www.ncbi.nlm.nih.gov/pubmed/26071911
http://dx.doi.org/10.1186/s12891-015-0602-6
_version_ 1782376094890983424
author Niccoli, Laura
Cassarà, Emanuele
Kaloudi, Olga
Nannini, Carlotta
Romagnoli, Micaela
Cantini, Fabrizio
author_facet Niccoli, Laura
Cassarà, Emanuele
Kaloudi, Olga
Nannini, Carlotta
Romagnoli, Micaela
Cantini, Fabrizio
author_sort Niccoli, Laura
collection PubMed
description BACKGROUND: Asbestosis is characterized by lung and pleural fibrosis and by immune system dysregulation, with autoantibody production and systemic immune-mediated disease. No specific therapies are available for asbestosis. Recently, the pivotal pathogenic role exerted by interleukin-1beta has been recently reported. CASE PRESENTATION: We treated with anti-interleukin 1 beta targeted antibody canakinumab a 67 year old man with asbestosis and long lasting systemic autoimmune features. A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months. CONCLUSION: This case suggests new perspectives for the treatment of asbestosis and its systemic features.
format Online
Article
Text
id pubmed-4465479
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44654792015-06-15 Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report Niccoli, Laura Cassarà, Emanuele Kaloudi, Olga Nannini, Carlotta Romagnoli, Micaela Cantini, Fabrizio BMC Musculoskelet Disord Case Report BACKGROUND: Asbestosis is characterized by lung and pleural fibrosis and by immune system dysregulation, with autoantibody production and systemic immune-mediated disease. No specific therapies are available for asbestosis. Recently, the pivotal pathogenic role exerted by interleukin-1beta has been recently reported. CASE PRESENTATION: We treated with anti-interleukin 1 beta targeted antibody canakinumab a 67 year old man with asbestosis and long lasting systemic autoimmune features. A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months. CONCLUSION: This case suggests new perspectives for the treatment of asbestosis and its systemic features. BioMed Central 2015-06-14 /pmc/articles/PMC4465479/ /pubmed/26071911 http://dx.doi.org/10.1186/s12891-015-0602-6 Text en © Niccoli et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Niccoli, Laura
Cassarà, Emanuele
Kaloudi, Olga
Nannini, Carlotta
Romagnoli, Micaela
Cantini, Fabrizio
Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
title Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
title_full Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
title_fullStr Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
title_full_unstemmed Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
title_short Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
title_sort systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465479/
https://www.ncbi.nlm.nih.gov/pubmed/26071911
http://dx.doi.org/10.1186/s12891-015-0602-6
work_keys_str_mv AT niccolilaura systemicautoimmunediseaseinasbestosisrapidlyrespondingtoantiinterleukin1betaantibodycanakinumabacasereport
AT cassaraemanuele systemicautoimmunediseaseinasbestosisrapidlyrespondingtoantiinterleukin1betaantibodycanakinumabacasereport
AT kaloudiolga systemicautoimmunediseaseinasbestosisrapidlyrespondingtoantiinterleukin1betaantibodycanakinumabacasereport
AT nanninicarlotta systemicautoimmunediseaseinasbestosisrapidlyrespondingtoantiinterleukin1betaantibodycanakinumabacasereport
AT romagnolimicaela systemicautoimmunediseaseinasbestosisrapidlyrespondingtoantiinterleukin1betaantibodycanakinumabacasereport
AT cantinifabrizio systemicautoimmunediseaseinasbestosisrapidlyrespondingtoantiinterleukin1betaantibodycanakinumabacasereport

Ejemplares similares